Drug intelligence / Profile preview

bromopride

Development stage
Phase 4
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous
01

Overview

Bromopride is a substituted benzamide and dopamine antagonist with prokinetic and antiemetic properties, closely related to metoclopramide but distinguished by a bromine atom in place of chlorine. It acts primarily as a selective antagonist at dopamine D2 receptors in both the central nervous system and gastrointestinal tract, thereby inhibiting dopamine-mediated relaxation of the GI tract, enhancing gastric motility, accelerating gastric emptying, and reducing symptoms such as nausea and vomiting. Its clinical uses include treatment of nausea and vomiting—including postoperative nausea—gastroesophageal reflux disease (GERD), preparation for endoscopy or radiographic studies of the GI tract, hiccups, decreased appetite, flatulence when used in combination products, and management of gastrointestinal adverse effects from radiation therapy. It is generally well tolerated; common side effects include somnolence and fatigue; rare extrapyramidal symptoms may occur[1][2][4][6].

Brand names
DigesanPlaMetBromopridaBropinDigesigmaDigespridDigestalineDigestilDigestinaFágicoFurolLipolarModulanzimeOptimid DigestOranorexOraxialPridecilPrimet EnzimaticoSoftinValoprideYungprideProcirex
Other names
Bromopridum (Latin)Bromoprid (German)Bromopride (French)Bromoprida (Spanish)
02

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on bromopride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromopride.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call